Fig. 1From: Low Annexin A1 level in HTLV-1 infected patients is a potential biomarker for the clinical progression and diagnosis of HAM/TSPQuantification of (a) ANXA1, (b) FPR1, (c) FPR2 and (d) FPR3 mRNA levels in whole blood from the control group (CG), asymptomatic (AS) patients and patients diagnosed with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). RQ: relative quantification. *Median (Kruskal-Wallis test)Back to article page